We are testing a new drug, ORIC-114, for patients with advanced solid tumors that have EGFR or HER2 alterations. The study will assess its safety and effectiveness alone and with chemotherapy.
Health conditions and diseases that the clinical trial is designed to study and treat.
Solid tumors are abnormal masses of tissue that can occur in various organs and are characterized by uncontrolled cell growth. They can be benign (non-cancerous) or malignant (cancerous), leading to various symptoms depending on their location.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.